Despite ushering in the weight-loss injectable craze and reaching a whopping $604 billion market cap in March 2024, Novo has for the past 18 months suffered hit after financial hit as compounding companies cut into its profit margin by selling cheaper, off-brand Ozempic - and as Eli Lilly, the makers of rival jabs Mounjaro and Zepbound, surged ahead thanks to promising news about its orforglipron GLP-1 pill.
Berkeley's hiring freeze aims to mitigate a budget deficit through summer 2026, reflecting the city's fiscal challenges due to dwindling one-time resources and economic uncertainty.